Johnson & Johnson has applied for authorisation for its coronavirus vaccine in the EU with a decision possible by the middle of March, the European Medicines Agency has said. "EMA has received an application for conditional marketing authorisation for a Covid-19 vaccine developed by Janssen-Cilag International N.V.," the Amsterdam-based regulator said, referring to J&J's European subsidiary.
Johnson & Johnson said that its single-dose vaccine was 66% effective in preventing Covid-19 in a large trial against multiple variants across three continents.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe Covid-19 varied from 72% in the US, to 66% in Latin America and just 57% in South Africa, from where